*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · preclinical | PMID 41490200 |
| 2026 | Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry Journal of pharmaceutical and biomedical analysis · preclinical | PMID 41138283 |
| 2024 | Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples Journal of mass spectrometry : JMS · preclinical | PMID 38197510 |
| 2023 | Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples Analytical biochemistry · preclinical | PMID 37806509 |
| 2023 | In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides Biomedical chromatography : BMC · preclinical | PMID 37688464 |
| 2023 | Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis Electrophoresis · preclinical | PMID 36787346 |
| 2022 | An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS Journal of pharmaceutical and biomedical analysis · preclinical | PMID 35298973 |
| 2022 | Probing for peptidic drugs (2-10 kDa) in doping control blood samples Analytical science advances · preclinical | PMID 38716080 |
| 2021 | Advances in the detection of growth hormone releasing hormone synthetic analogs Drug testing and analysis · preclinical | PMID 34665524 |
| 2021 | A potentially effective drug for patients with recurrent glioma: sermorelin Annals of translational medicine · preclinical | PMID 33842627 |
| 2020 | Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males Translational andrology and urology · preclinical | PMID 32257855 |
| 2016 | Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS Analytical and bioanalytical chemistry · preclinical | PMID 26879649 |
| 2006 | Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical interventions in aging · preclinical | PMID 18046908 |
| 2003 | PEGylation of growth hormone-releasing hormone (GRF) analogues Advanced drug delivery reviews · preclinical | PMID 14499707 |
| 1999 | Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · preclinical | PMID 18031173 |
Sermorelin (Sermorelin (GHRH 1-29)). Synthetic analogue of the first 29 amino acids of GHRH (the active fragment). Stimulates pituitary GH release; historically used as a diagnostic agent for GH deficiency.
Commonly discussed uses: GH-axis support / anti-aging (off-label clinic use), historical: paediatric GH-deficiency diagnosis. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic analogue of the first 29 amino acids of GHRH (the active fragment). Stimulates pituitary GH release; historically used as a diagnostic agent for GH deficiency.
Reported considerations: injection-site reaction, flushing, headache. There is both human and animal/preclinical research, though the depth and quality vary by indication. Original branded product discontinued; current use is compounded/off-label. Not WADA-permitted in sport. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 100mcg, typical 200-300mcg before sleep, high 500mcg. Administration: subcutaneous. Half-life: ~10-20 min.
Australian status: Not ARTG-registered currently; prescription if compounded. Original branded product discontinued; current use is compounded/off-label. Not WADA-permitted in sport. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2ml BAC water per 5mg vial; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): Sermorelin + GHRP (anecdotal GH-axis stack). Stacking increases interaction/safety uncertainty.